DELCATH SYSTEMS, INC. — Director's Dealing 2023

Aug 21, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DELCATH SYSTEMS, INC. (DCTH)
CIK: 0000872912
Period of Report: 2023-08-18

Reporting Person: MICHEL GERARD J (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-08-18	Common Stock	X	31110	$4.50	Acquired	228345	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-08-18	Tranche A Warrants to Purchase Common Stock	$4.50	X	31110	Disposed		Common Stock (31110)	Direct

Footnotes

F1: The Tranche A Warrants are immediately exercisable.

F2: The Tranche A Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of its receipt of written approval from the U.S. Food and Drug Administration of its New Drug Application for HEPZATO (the "FDA Approval") and (ii) March 31, 2026.

F3: The common stock and Tranche A and Tranche B Warrants were acquired in the issuer's private placement of common stock and warrants, issued as part of a unit. The per unit purchase price was $5.09, including a purchase price of $4.84 per share of common stock and $0.125 for each of the Tranche A and Tranche B Warrants. Each unit consisted of one share of common stock and an accompanying common stock warrant valued at 140% of the aggregate purchase price (the Tranche A Warrant) and an accompanying common stock warrant valued at 100% of the aggregate purchase price (the Tranche B Warrant).